Potential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in females

International Journal of Women's Health

Volumn 4, Issue 1, 2012, Pages 341-350

  Tan, D H S ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

CAPRISA 004; Herpes simplex virus type 2; Microbicide; Tenofovir

Indexed keywords

ACICLOVIR; ADEFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; CARBOPOL 974P; CARRAGEENAN; CIDOFOVIR; CONTRACEPTIVE AGENT; EMTRICITABINE; GS 7340; LEVONORGESTREL; PLACEBO; PRO 2000; SURFACTANT; TENOFOVIR; TENOFOVIR DIPHOSPHATE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; GEL; GENITAL HERPES; GENITAL ULCER; HEPATITIS B; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HETEROSEXUAL FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION RISK; LOW DRUG DOSE; MATERNAL MORBIDITY; MIXED INFECTION; NEWBORN MORBIDITY; NONHUMAN; PATIENT COMPLIANCE; PUBLIC HEALTH; REVIEW; RISK REDUCTION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

EID: 84864864009     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S27601     Document Type: Review

References (87)

1. Paz-Bailey G, Ramaswamy M, Hawkes SJ, Geretti AM. Herpes simplex virus type 2: epidemiology and management options in developing countries. Sex Transm Infect. 2007;83:16-22.
2. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med. 1992;116:197-202.
3. Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med. 1983;98:958-972.
4. Karim SS, Karim Q. Effectiveness and safety of vaginal microbicide 1% tenofovir gel for prevention of HIV infection in women. Abstract TUSS0204 presented at the XVIII International AIDS Conference, July 18-23, 2010, Vienna, Austria.
5. Abdool Karim Q, Abdool Karim SS, Frohlich JA, etal. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-1174.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed April 10, 2012.
7. Thompson MA, Aberg JA, Cahn P, etal. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321-333.
8. European AIDS Clinical Society. Guidelines: clinical management and treatment of HIV infected adults in Europe. Available at: http://www.europeanaidsclinicalsociety.org/index.php?option=com_content&view=article&id=59&Itemid=41. Accessed June 2, 2012.
9. Gazzard BG, Anderson J, Babiker A, etal. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9:563-608.
10. World Health Organisation. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Available at: http://www.who.int/hiv/pub/arv/advice/en/index.html. Accessed July 2, 2012.
11. Van Damme L, Ramjee G, Alary M, etal. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002;360:971-977.
12. Peterson L, Nanda K, Opoku BK, etal. SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One. 2007;2:e1312.
13. Skoler-Karpoff S, Ramjee G, Ahmed K, etal. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1977-1987.
14. McCormack S, Ramjee G, Kamali A, etal. PRO2000 vaginal gel for prevention of HIV-1infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010;376:1329-1337.
15. Abdool Karim SS, Richardson BA, Ramjee G, etal. Safety and effectiveness of BufferGel and 0.5% PRO2000gel for the prevention of HIV infection in women. AIDS. 2011;25:957-966.
16. Mayer KH, Maslankowski LA, Gai F, etal. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006;20:543-551.
17. Hillier SL, Joshi S, Cyrus-Cameron E, etal. Safety and acceptability of coitally dependent use of 1% tenofovir gel over six months of use. Abstract 655 presented at the Microbicides Conference, February 24-27, 2008, New Delhi, India.
18. Cranage M, Sharpe S, Herrera C, etal. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med. 2008;5:e157.
19. Parikh UM, Dobard C, Sharma S, etal. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol. 2009;83:10358-10365.
20. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, etal. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1microbicide. PLoS One. 2010;5:e9310.
21. Cheshenko N, Keller MJ, MasCasullo V, etal. Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agents Chemother. 2004;48:2025-2036.
22. Zacharopoulos VR, Phillips DM. Vaginal formulations of carrageenan protect mice from herpes simplex virus infection. Clin Diagn Lab Immunol. 1997;4:465-468.
23. Maguire RA, Bergman N, Phillips DM. Comparison of microbicides for efficacy in protecting mice against vaginal challenge with herpes simplex virus type 2, cytotoxicity, antibacterial properties, and sperm immobilization. Sex Transm Dis. 2001;28:259-265.
24. Zeitlin L, Hoen TE, Achilles SL, etal. Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models. Sex Transm Dis. 2001;28:417-423.
25. Keller MJ, Zerhouni-Layachi B, Cheshenko N, etal. PRO 2000gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J Infect Dis. 2006;193:27-35.
26. Balzarini J, Holy A, Jindrich J, etal. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother. 1993;37:332-338.
27. De Clercq E. The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. Antiviral Res. 2007;75:1-13.
28. Andrei G, Lisco A, Vanpouille C, etal. Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe. 2011;10:379-389.
29. Tan DH, Kaul R, Raboud JM, Walmsley SL. No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults. AIDS. 2011;25:207-210.
30. Grant RM, Lama JR, Anderson PL, etal. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-2599.
31. Lama J, Mayer K, Schechter M, etal. Oral TDF and its impact in HSV-2 acquisition and clinical expression. Abstract 1003 presented at the 18th Conference on Retroviruses and Opportunistic Infections, February 27-March 2, 2011, Boston, MA.
32. Kashuba AD, Abdool Karim SS, Kraft E, etal. Do systemic and genital tract tenofovir concentrations predict HIV seroconversion in the CAPRISA 004 tenofovir gel trial. Abstract TUSS0503 presented at the XVIII International AIDS Conference, July 18-23, 2010, Vienna, Austria.
33. Patterson KB, Prince HA, Kraft E, etal. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3:112-114.
34. Dumond JB, Yeh RF, Patterson KB, etal. Antiretroviral drug exposure in the female genital tract: implications for oral pre-and post-exposure prophylaxis. AIDS. 2007;21:1899-1907.
35. Kwara A, Delong A, Rezk N, etal. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis. 2008;46:719-725.
36. Schwartz JL, Rountree W, Kashuba AD, etal. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One. 2011;6:e25974.
37. Siberry GK, Williams PL, Mendez H, etal. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS. 2012;26:1151-1159.
38. Johnston C, Magaret A, Selke S, Remington M, Corey L, Wald A. Herpes simplex virus viremia during primary genital infection. J Infect Dis. 2008;198:31-34.
39. Brown ZA, Selke S, Zeh J, etal. The acquisition of herpes simplex virus during pregnancy. N Engl J Med. 1997;337:509-515.
40. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis. 2002;185:45-52.
41. Reynolds SJ, Risbud AR, Shepherd ME, etal. Recent herpes simplex virus type 2infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis. 2003;187:1513-1521.
42. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006;20:73-83.
43. Mark KE, Wald A, Magaret AS, etal. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis. 2008;198:1141-1149.
44. Mark KE, Wald A, Magaret AS, etal. Rapidly cleared episodes of oral and anogenital herpes simplex virus shedding in HIV-infected adults. J Acquir Immune Defic Syndr. 2010;54:482-488.
45. Schiffer JT, Abu-Raddad L, Mark KE, etal. Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model. Sci Transl Med. 2009;1:7ra16.
46. Johnston C, Saracino M, Kuntz S, etal. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet. 2012;379:641-647.
47. Cunningham AL, Turner RR, Miller AC, Para MF, Merigan TC. Evolution of recurrent herpes simplex lesions. An immunohistologic study. J Clin Invest. 1985;75:226-233.
48. Koelle DM, Abbo H, Peck A, Ziegweid K, Corey L. Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions. J Infect Dis. 1994;169:956-961.
49. Koelle DM, Corey L, Burke RL, etal. Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J Virol. 1994;68:2803-2810.
50. Boily MC, Dimitrov D, Mâsse B. How much of the overall microbicide effectiveness against HIV is due to the protection of TFV gel against HSV-2 The CAPRISA-004 trial. Abstract 999 presented at the 18th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2011, Boston, MA.
51. Gupta R, Warren T, Wald A. Genital herpes. Lancet. 2008;370:2127-2137.
52. Augenbraun M, Feldman J, Chirgwin K, etal. Increased genital shedding of herpes simplex virus type 2in HIV-seropositive women. Ann Intern Med. 1995;123:845-847.
53. Bagdades EK, Pillay D, Squire SB, O'Neil C, Johnson MA, Griffiths PD. Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection. AIDS. 1992;6:1317-1320.
54. Safrin S, Ashley R, Houlihan C, Cusick PS, Mills J. Clinical and serologic features of herpes simplex virus infection in patients with AIDS. AIDS. 1991;5:1107-1110.
55. Siegal FP, Lopez C, Hammer GS, etal. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med. 1981;305:1439-1444.
56. Yudin MH, Kaul R. Progressive hypertrophic genital herpes in an HIV-infected woman despite immune recovery on antiretroviral therapy. Infect Dis Obstet Gynecol. 2008;2008:592532.
57. Holmes A, McMenamin M, Mulcahy F, Bergin C. Thalidomide therapy for the treatment of hypertrophic herpes simplex virus-related genitalis in HIV-infected individuals. Clin Infect Dis. 2007;44:e96-e99.
58. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev. 2003;16:114-128.
59. Sheth PM, Sunderji S, Shin LY, etal. Coinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activation. J Infect Dis. 2008;197:1394-1401.
60. Kaul R, Pettengell C, Sheth PM, etal. The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission. J Reprod Immunol. 2008;77:32-40.
61. Gray RH, Li X, Wawer MJ, etal. Determinants of HIV-1 load in subjects with early and later HIV infections, in a general-population cohort of Rakai, Uganda. J Infect Dis. 2004;18:1209-1215.
62. Tan DHS, Murphy K, Shah PS, Walmsley SL. Systematic review of the impact of herpes simplex virus type 2 on HIV disease progression. Abstract 305 presented at the Ontario HIV Treatment Network Research Conference, November 14-15, 2011, Toronto, Canada.
63. Lingappa JR, Baeten JM, Wald A, etal. Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet. 2010;375:824-833.
64. Reynolds SJ, Makumbi F, Newell K, etal. Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial. Lancet Infect Dis. 2012;12:441-448.
65. McMahon MA, Siliciano JD, Lai J, etal. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem. 2008;283:31289-31293.
66. Lisco A, Vanpouille C, Tchesnokov EP, etal. Acyclovir is activated into a HIV-1reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe. 2008;4:260-270.
67. Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr. 2004;35:435-445.
68. Gray RH, Wawer MJ, Brookmeyer R, etal. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357:1149-1153.
69. Malcolm RK, Edwards KL, Kiser P, Romano J, Smith TJ. Advances in microbicide vaginal rings. Antiviral Res. 2010;88 Suppl 1:S30-S39.
70. Johnson TJ, Gupta KM, Fabian J, Albright TH, Kiser PF. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur J Pharm Sci. 2010;39:203-212.
71. Friend DR. Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission. Expert Opin Drug Deliv. 2012;9:417-427.
72. Blish CA, Baeten JM. Hormonal contraception and HIV-1 transmission. Am J Reprod Immunol. 2011;65:302-307.
73. Kelly L, Carr D, Clark MR, etal. In vivo release in sheep of a dual loaded microbicide polyurethane vaginal ring. Paper presented at the American Association of Pharmaceutical Scientists Annual Meeting and Exposition, October 23-27, 2011, Washington, DC.
74. Moss JA, Malone AM, Smith TJ, etal. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrob Agents Chemother. 2012;56:875-882.
75. Zhang T, Sturgis TF, Youan BB. pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission. Eur J Pharm Biopharm. 2011;79:526-536.
76. Alukda D, Sturgis T, Youan BB. Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention. J Pharm Sci. 2011;100:3345-3356.
77. Ham AS, Ugaonkar SR, Shi L, etal. Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection. J Pharm Sci. 2012;101:1423-1435.
78. Kiser PF, Mahalingam A, Fabian J, etal. Design of tenofovir-UC781 combination microbicide vaginal gels. J Pharm Sci. 2012;101:1852-1864.
79. Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother. 2011;66:240-250.
80. Moss JA, Baum MM, Malone AM, etal. Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings. AIDS. 2012;26:707-710.
81. Mesquita PM, Rastogi R, Segarra TJ, etal. Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother. 2012;67(7):1730-1738.
82. Ruane P, DeJesus E, Berger D, etal. GS-7340 25mg and 40mg demonstrate superior efficacy to tenofovir disoproxil fumarate 300mg in a 10-day monotherapy study of HIV-1+ patients. Abstract 103 presented at the 19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012, Seattle, WA.
83. Anton P, Cranston R, Carballo-Dieguez A, etal. RMP-02/MTN-006: A phase 1 placebo-controlled trial of rectally applied 1% vaginal TFV gel with comparison to oral TDF. Abstract 34LB presented at the 18th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2011, Boston, MA.
84. McGowan I, Hoesley C, Andrew P, etal. MTN-007: a Phase 1 randomized, double-blind, placebo-controlled rectal safety and acceptability study of tenofovir 1% gel. Abstract 34LB presented at the19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012, Seattle, WA.
85. Fischer W, Hunt G, Sibeko S, etal. Tenofovir resistance mutation frequencies assessed by deep pyrosequencing of plasma virus from breakthrough HIV infections: CAPRISA 004microbicide trial. Abstract 1063 presented at the 19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012, Seattle, WA.
86. Wei X, Morris L, Naranbhai V, etal. Sensitive tenofovir resistance screening of HIV-1 from the genital tract of women with breakthrough infections: CAPRISA 004 tenofovir gel trial. Abstract 33 presented at the 19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012, Seattle, WA.
87. Tan DH, Kaul R, Walsmley S. Left out but not forgotten: should closer attention be paid to coinfection with herpes simplex virus type 1 and HIV? Can J Infect Dis Med Microbiol. 2009;20:e1-e7.